European cardiologists welcome lower cholesterol targets

9 September 2007

According to the results of a survey presented at the European Society of Cardiology Congress in Austria, 94% of European cardiologists questioned supported the new targets for total cholesterol of <4.5mmol/l and low-density lipoprotein cholesterol of <2.5mmol/l, for high risk patients. The survey, which was sponsored by Merck, Sharp & Dohme and Schering-Plough, also revealed that 78% of respondents felt that national cholesterol guidelines were not being followed.

The new guidelines, which are the fourth set published by the European Joint Task Force, maintained the previously-issued total cholesterol target of <4.5mmol/l and low-density lipoprotein goal of <2.5mmol/l, but added that, if feasible, treatment should aim to achieve TC <4mmol/ and LDL-C of <2mmol/l. In the UK, where cholesterol targets are set at <5mmol/l and <3mmol/l, respectively, 85% of UK cardiologists supported the new optional lower cholesterol guidelines.

The study also showed that a high proportion of respondents, nearly 81%, said that many high-risk patients with hyperlipidemia and or hypercholeterolemia may be insufficiently treated with current statin-based therapies, and that 79% believed that physicians were reluctant to prescribe high-dose statins due to concerns over safety and tolerability.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



More ones to watch >




Today's issue

Company Spotlight